What is Ablative Solutions?
Founded in 2011 and headquartered in Wakefield, Massachusetts, Ablative Solutions is a medical device innovator dedicated to addressing the critical, unmet needs of patients suffering from hypertension. The company's core technology, the Peregrine System, is designed to target the overactive sympathetic nervous system. This physiological intervention holds potential for treating a spectrum of conditions, including heart failure, kidney disease, metabolic syndrome, and sleep apnea. By focusing on neuro-modulation, Ablative Solutions is carving out a distinct market position at the intersection of interventional cardiology and chronic disease management, aiming to provide a non-pharmacological alternative for patients who remain resistant to traditional antihypertensive medications.
How much funding has Ablative Solutions raised?
Ablative Solutions has raised a total of $149.8M across 9 funding rounds:
Debt
$3M
Series A
$5.4M
Debt
$8M
Series B
$9.5M
Series C
$14.6M
Unspecified
$2.5M
Private Equity
$11.4M
Debt
$4M
Series D
$91.4M
Debt (2011): $3.1M, investors not publicly disclosed
Series A (2012): $5.4M led by BioStar Capital and Michigan Accelerator Fund
Debt (2013): $8M, investors not publicly disclosed
Series B (2014): $9.5M featuring Michigan Accelerator Fund I and BioStar Capital
Series C (2015): $14.6M, investors not publicly disclosed
Unspecified (2015): $2.5M, investors not publicly disclosed
Private Equity (2017): $11.4M, investors not publicly disclosed
Debt (2017): $4M, investors not publicly disclosed
Series D (2022): $91.4M featuring BioStar Capital, Invus Opportunities, and Gilde Healthcare
Key Investors in Ablative Solutions
BioStar Capital
BioStar Capital is a visionary healthcare investor focused on transformative medical devices. The company combines business acumen with clinical expertise, leveraging a collaboration of healthcare clinicians, medical thought leaders, and financial professionals.
Gilde Healthcare
Gilde Healthcare is a specialized healthcare investment firm managing over 1.4 billion euros across three fund strategies, focusing on businesses that enable better care at lower costs.
Michigan Accelerator Fund
Michigan Accelerator Fund provides strategic support to early-stage companies, focusing on high-growth potential ventures within the technology and healthcare sectors.
What's next for Ablative Solutions?
With the recent influx of capital, Ablative Solutions is poised to transition from late-stage clinical validation to broader commercial readiness. The strategic roadmap likely involves scaling the Peregrine System's clinical trials to establish robust efficacy data, which is essential for regulatory approval and subsequent market penetration. As the company navigates the complexities of the medical device landscape, the focus will remain on demonstrating that their sympathetic nervous system intervention can deliver sustainable, long-term health outcomes. Investors are closely monitoring the firm's ability to integrate its technology into standard clinical workflows, which will be a primary driver for future valuation growth and potential exit opportunities in the high-stakes medtech arena.
See full Ablative Solutions company page
